BanderasNews
Puerto Vallarta Weather Report
Welcome to Puerto Vallarta's liveliest website!
Contact UsSearch
Why Vallarta?Vallarta WeddingsRestaurantsWeatherPhoto GalleriesToday's EventsMaps
 NEWS/HOME
 EDITORIALS
 ENTERTAINMENT
 VALLARTA LIVING
 PV REAL ESTATE
 TRAVEL / OUTDOORS
 HEALTH / BEAUTY
 SALON & SPA SERVICES
 HEALTH FOR WOMEN
 HEALTH FOR MEN
 DENTAL HEALTH
 ON ADDICTION
 RESOURCES
 SPORTS
 DAZED & CONFUSED
 PHOTOGRAPHY
 CLASSIFIEDS
 READERS CORNER
 BANDERAS NEWS TEAM
Sign up NOW!

Free Newsletter!
Puerto Vallarta News NetworkHealth & Beauty | May 2007 

Brazil Breaks Merck Drug Patent in Major Victory for AIDS Activism, Says AHF
email this pageprint this pageemail usPRNewswire


Urging a major shift in U.S. policy, some health experts are recommending that virtually all Americans be tested routinely for the AIDS virus, much as they are for cancer and other diseases. Joe Mendoza, manager of the AIDS Healthcare Foundation mobile testing program, pricks a volunteer's finger to demonstrate how a lancet from the OraQuick Rapid HIV-1 Antibody Test kit is used to obtain a blood sample.
Amid news that the President of Brazil, Luiz Inacio Lula da Silva, today will announce Brazil's intention to issue a compulsory license for Merck's HIV/AIDS drug Efavirenz, AIDS Healthcare Foundation (AHF), the US' largest provider of HIV/AIDS healthcare, education and prevention and operator of free AIDS treatment clinics in the US, Africa, Latin America/Caribbean and Asia, hailed the move as a victory for global AIDS activism and AIDS patients worldwide. President Lula de Silva's decision comes after reports of a breakdown in negotiations between Brazil and the drug giant Merck.

According to the country's health ministry, Brazil had asked Merck to cut the price of Efavirenz to 65 cents a pill from $1.57 and Merck had refused. Brazil's decision to issue a compulsory license for the drug, which will allow the country to manufacture the drug or to buy generic versions, comes on the heels of Thailand's recent move to issue a compulsory license for Abbott's AIDS drug, Kaletra and in the lead-up to an AIDS Healthcare Foundation-hosted discussion regarding AIDS drug-pricing for Mexico, scheduled for June 4th in Mexico City.

"In announcing its intention to issue a compulsory license for Merck's AIDS drug Efavirenz, Brazil is once again leading the way to affordable AIDS drug access for every nation," added Michael Weinstein, President of AIDS Healthcare Foundation. "We salute the courage of countries such as Brazil, Thailand and Mexico who are fighting to ensure drug access for AIDS patients the world over. Today is a victory for AIDS activists and patients everywhere, and proof that drug companies will go down in defeat every time they place themselves in the way of justice for AIDS patients."

Flexibilities under the World Trade Organization's (WTO) Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement allow governments to issue compulsory licenses (including royalty payment to the patent owner) if the country deems it necessary and appropriate to protect the health of its citizens. Brazil has been widely praised by global AIDS treatment activists for its government AIDS program, which provides free medication for anyone who needs it.

In the Latin American region, AIDS Healthcare Foundation operates free HIV/AIDS treatment clinics in Guatemala (Quetzaltenango) and in Mexico (Tijuana and Puerto Vallarta).

Source: AIDS Healthcare Foundation



In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving
the included information for research and educational purposes • m3 © 2008 BanderasNews ® all rights reserved • carpe aestus